UK Based Med Device-Diagnostic files IPO: Quotient focuses on Blood Transfusion Diagnostics.
March 8, 2014
Quotient, a U.K. focused on blood transfusion diagnostics, unveiled plans for an initial public offering that would raise as much as $75 million. The move continues a steady trickle of IPO movement among testing companies that began late last fall.
Share pricing and other details aren't out yet, but the company said it would rely on UBS Securities, Cowen & Company and Robert W. Baird & Co. to serve as joint bookrunners for the deal. Plans call for trading on Nasdaq, using the symbol "QTNT," according to the S-1 filing.
March 8, 2014
Quotient, a U.K. focused on blood transfusion diagnostics, unveiled plans for an initial public offering that would raise as much as $75 million. The move continues a steady trickle of IPO movement among testing companies that began late last fall.
Share pricing and other details aren't out yet, but the company said it would rely on UBS Securities, Cowen & Company and Robert W. Baird & Co. to serve as joint bookrunners for the deal. Plans call for trading on Nasdaq, using the symbol "QTNT," according to the S-1 filing.
No comments:
Post a Comment